The purpose of this study is to screen chemotherapy drugs currently used to treat lung cancer and determine the most effective treatment based on results of chemo sensitivity testing on the patients own cancer cells in the laboratory. The results of this screening will not influence the patients treatment.
The chemosensitivity assay will be performed on tissue obtained during the diagnostic fine needle aspiration, core biopsy, or excisional biopsy of the lung lesion. Cancer cells (Bulk of tumor) and Cancer Stem Cells (CSCs) will be isolated and expanded in the laboratory. The drug screening assay will be used to evaluate the response of the CSCs and of the cancer cells to the various chemotherapy regimens.
Study Type
OBSERVATIONAL
Enrollment
45
Cabell Huntington Hospital
Huntington, West Virginia, United States
Tumor size
Tumor response will be evaluated (progression/regression) by CT scan at 3 months from therapy start. Clinical response to chemotherapy of lung cancer tumor cells versus lung cancer stem cells to standard of care chemo drugs will be evaluated and correlated to predicted drug by ex vivo assay.
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.